Industry Research Reports
Home > Reports > Service & Software > Global AI In Drug Development Market Outlook, In‑Depth Analysis & Forecast to 2032
Global AI In Drug Development Market Outlook, In‑Depth Analysis & Forecast to 2032
Industry: Service & Software
Published Date: 2026-03-12
Pages: 144 Pages
Report ld: 6242707
Request Sample
Customized Report
- Description
- Table of Contents
- Table of Figures
- Related Reports
PDF Download
- Description
- Table of Contents
- Table of Figures
- Related Reports
- PDF Download
AI In Drug Development Market Size(US$)
CAGR 2026-2032
56.0%
Market Size,2032
USD 12,590
Million
Market Snapshot
Market Size in 2026 (Value)
US$ 873 million
Market Forecast in 2032(Value)
US$ 12,590 million
CAGR
56.0%
Years Considered
2021-2032
Base Year
2026
Forecast Period
2026-2032
Source: Secondary research, interviews with experts, and QYResearch analysis
The global AI In Drug Development market is projected to grow from US$ 581 million in 2025 to US$ 12590 million by 2032, at a CAGR of 56.0% (2026-2032), driven by critical product segments and diverse end‑use applications.
AI in drug development, also known as AI-assisted drug discovery and development, refers to the application of artificial intelligence (AI) technologies, including machine learning, deep learning, natural language processing, and big data analytics, to accelerate and optimize various stages of drug research and development. This encompasses a wide range of complex and time-consuming processes, from disease target identification, drug molecule design and optimization, high-throughput screening, and preclinical research, to clinical trial design and management, and drug repurposing. By analyzing vast amounts of biomedical data, chemical structure data, genomic data, and clinical trial data, AI can uncover patterns and correlations that are difficult to detect through traditional methods, thereby enhancing the efficiency of drug discovery, reducing research and development costs, shortening time-to-market for new drugs, and improving the overall success rate of drug development.
From a downstream perspective, Biopharmaceuticals accounted for % of 2025 revenue, surging to US$ million by 2032 (CAGR: % from 2026–2032).
AI In Drug Development leading players (including Pfizer, AstraZeneca, Johnson & Johnson, Novartis, Sanofi, Roche, Insilico Medicine, Exscientia, BenevolentAI, Recursion Pharmaceuticals, etc.), dominate supply; the top five capture approximately % of global revenue, with Pfizer leading 2025 sales at US$ million.
Regional Outlook:
North America rose from US$ million in 2025 to a forecast US$ million by 2032 (CAGR %).
Asia‑Pacific will expand from US$ million to US$ million (CAGR %), led by China (US$ million in 2025, % share rising to % by 2032), Japan (CAGR %), South Korea (CAGR %), and Southeast Asia (CAGR %).
Europe is set to grow from US$ million to US$ million (CAGR %), with Germany projected to hit US$ million by 2032 (CAGR %).
Report Includes:
This definitive report equips business leaders, decision-makers, and stakeholders with a 360° view of the global AI In Drug Development market across value chain. It analyzes historical revenue data (2021–2025) and delivers forecasts through 2032, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customer distribution pattern.
Granular regional insights cover five major markets (North America, Europe, APAC, South America, and MEA) with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players (revenue, margins, pricing strategies, and major customers) and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middle stream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
MARKET SEGMENTATION
By Company
- Pfizer
- AstraZeneca
- Johnson & Johnson
- Novartis
- Sanofi
- Roche
- Insilico Medicine
- Exscientia
- BenevolentAI
- Recursion Pharmaceuticals
- Atomwise
- Isomorphic Labs
- XtalPi
- Deep Genomics
- Relay Therapeutics
Consumption by Region
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
- Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Segment by Type
- Software
- Services
Segment by Application
- Biopharmaceuticals
- Synthetic Pharmaceuticals
- Others
CHAPTER OUTLINE
Chapter 1: Defines the AI In Drug Development study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential
Chapter 2: Offers current market state, projects global revenue and sales to 2032, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape: ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves
Chapter 4: Unlocks high margin product segments: compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities: evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application
Chapter 6: North America: breaks down market size by Application and country, profiles key players and assesses growth drivers and barriers
Chapter 7: Europe: analyses regional market by Application and players, flagging drivers and barriers
Chapter 8: Asia Pacific: quantifies market size by Application, and region/country, profiles top players, and uncovers high potential expansion areas
Chapter 9: Central & South America: measures market size by Application, and country, profiles top players, and identifies investment opportunities and challenges
Chapter 10: Middle East and Africa: evaluates market size by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth: details product specs, revenue, margins; top-tier players 2025 sales breakdowns by product type, by Application, by region SWOT analysis, and recent strategic developments
Chapter 12: Value chain and ecosystem: analyses upstream, midstream, plus downstream channels
Chapter 13: Market dynamics: explores drivers, restraints, regulatory impacts, and risk mitigation strategies
Chapter 14: Actionable conclusions and strategic recommendations.
WHY THIS REPORT
Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to:
Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to:
Allocate capital strategically to high growth regions (Chapters 6-10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
QYRESEARCH'S STRENGTHS
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:
Market entry risks/opportunities by region
We identify regional market threats and growth prospects to guide your overseas layout.
Product mix optimization based on local practices
We adjust product portfolios in line with local consumption habits.
Competitor tactics in fragmented vs. consolidated markets
We unpack rivals’ operation strategies for scattered and highly concentrated industries.
Full Research Coverage
We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.
19 Years Industry Expertise
We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.
24/7 Fast Report Delivery
Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.
Localized Strategic Analysis
We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.
Market entry risks/opportunities by region
All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.
Market entry risks/opportunities by region
We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.
TABLE OF CONTENTS
1 Study Coverage
1.1 Introduction to AI In Drug Development: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global AI In Drug Development Market Size by Type, 2021 vs 2025 vs 2032
1.2.2 Software
1.2.3 Services
1.3 Market Segmentation by Application
1.3.1 Global AI In Drug Development Market Size by Application, 2021 vs 2025 vs 2032
1.3.2 Biopharmaceuticals
1.3.3 Synthetic Pharmaceuticals
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global AI In Drug Development Revenue Estimates and Forecasts (2021-2032)
2.2 Global AI In Drug Development Revenue by Region
2.2.1 Revenue Comparison: 2021 vs 2025 vs 2032
2.2.2 Historical and Forecasted Revenue by Region (2021-2032)
2.2.3 Global Revenue-Based Market Share by Region (2021-2032)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competitive Landscape
3.1 Global AI In Drug Development Players’ Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2021-2026)
3.1.2 Global Key Players’ Revenue Ranking (2024 vs 2025)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Players (2021 vs 2025)
3.2 Global AI In Drug Development Companies Headquarters and Service Footprint
3.3 Key Player Market Share by Product Type
3.3.1 Software: Market Share by Key Players
3.3.2 Services: Market Share by Key Players
3.4 Global AI In Drug Development Market Concentration and Dynamics
3.4.1 Global Market Concentration
3.4.2 Market Entry and Exit Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Product Segmentation
4.1 Global AI In Drug Development Market by Type
4.1.1 Global Revenue by Type (2021-2032)
4.1.2 Global Revenue-Based Market Share by Type (2021-2032)
4.2 Key Product Attributes and Differentiation
4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.3.1 High-Growth Niches and Adoption Drivers
4.3.2 Profitability Hotspots and Cost Drivers
4.3.3 Substitution Threats
5 Downstream Applications and Customers
5.1 Global AI In Drug Development Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2021-2032)
5.1.2 Revenue-Based Market Share by Application (2021-2032)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2021-2032)
6.2 North America Key Players’ Revenue in 2025
6.3 North America AI In Drug Development Market Size by Application (2021-2032)
6.4 North America Growth Accelerators and Market Barriers
6.5 North America AI In Drug Development Market Size by Country
6.5.1 North America Revenue Trends by Country
6.5.2 US
6.5.3 Canada
6.5.4 Mexico
7 Europe
7.1 Europe Market Size (2021-2032)
7.2 Europe Key Players’ Revenue in 2025
7.3 Europe AI In Drug Development Market Size by Application (2021-2032)
7.4 Europe Growth Accelerators and Market Barriers
7.5 Europe AI In Drug Development Market Size by Country
7.5.1 Europe Revenue Trends by Country
7.5.2 Germany
7.5.3 France
7.5.4 U.K.
7.5.5 Italy
7.5.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2021-2032)
8.2 Asia-Pacific Key Players’ Revenue in 2025
8.3 Asia-Pacific AI In Drug Development Market Size by Application (2021-2032)
8.4 Asia-Pacific Growth Accelerators and Market Barriers
8.5 Asia-Pacific AI In Drug Development Market Size by Region
8.5.1 Asia-Pacific Revenue Trends by Region
8.6 China
8.7 Japan
8.8 South Korea
8.9 Australia
8.10 India
8.11 Southeast Asia
8.11.1 Indonesia
8.11.2 Vietnam
8.11.3 Malaysia
8.11.4 Philippines
8.11.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2021-2032)
9.2 Central and South America Key Players’ Revenue in 2025
9.3 Central and South America AI In Drug Development Market Size by Application (2021-2032)
9.4 Central and South America Investment Opportunities and Key Challenges
9.5 Central and South America AI In Drug Development Market Size by Country
9.5.1 Central and South America Revenue Trends by Country (2021 vs 2025 vs 2032)
9.5.2 Brazil
9.5.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2021-2032)
10.2 Middle East and Africa Key Players’ Revenue in 2025
10.3 Middle East and Africa AI In Drug Development Market Size by Application (2021-2032)
10.4 Middle East and Africa Investment Opportunities and Key Challenges
10.5 Middle East and Africa AI In Drug Development Market Size by Country
10.5.1 Middle East and Africa Revenue Trends by Country (2021 vs 2025 vs 2032)
10.5.2 GCC Countries
10.5.3 Israel
10.5.4 Egypt
10.5.5 South Africa
11 Corporate Profile
11.1 Pfizer
11.1.1 Pfizer Corporation Information
11.1.2 Pfizer Business Overview
11.1.3 Pfizer AI In Drug Development Product Features and Attributes
11.1.4 Pfizer AI In Drug Development Revenue and Gross Margin (2021-2026)
11.1.5 Pfizer AI In Drug Development Revenue by Product in 2025
11.1.6 Pfizer AI In Drug Development Revenue by Application in 2025
11.1.7 Pfizer AI In Drug Development Revenue by Geographic Area in 2025
11.1.8 Pfizer AI In Drug Development SWOT Analysis
11.1.9 Pfizer Recent Developments
11.2 AstraZeneca
11.2.1 AstraZeneca Corporation Information
11.2.2 AstraZeneca Business Overview
11.2.3 AstraZeneca AI In Drug Development Product Features and Attributes
11.2.4 AstraZeneca AI In Drug Development Revenue and Gross Margin (2021-2026)
11.2.5 AstraZeneca AI In Drug Development Revenue by Product in 2025
11.2.6 AstraZeneca AI In Drug Development Revenue by Application in 2025
11.2.7 AstraZeneca AI In Drug Development Revenue by Geographic Area in 2025
11.2.8 AstraZeneca AI In Drug Development SWOT Analysis
11.2.9 AstraZeneca Recent Developments
11.3 Johnson & Johnson
11.3.1 Johnson & Johnson Corporation Information
11.3.2 Johnson & Johnson Business Overview
11.3.3 Johnson & Johnson AI In Drug Development Product Features and Attributes
11.3.4 Johnson & Johnson AI In Drug Development Revenue and Gross Margin (2021-2026)
11.3.5 Johnson & Johnson AI In Drug Development Revenue by Product in 2025
11.3.6 Johnson & Johnson AI In Drug Development Revenue by Application in 2025
11.3.7 Johnson & Johnson AI In Drug Development Revenue by Geographic Area in 2025
11.3.8 Johnson & Johnson AI In Drug Development SWOT Analysis
11.3.9 Johnson & Johnson Recent Developments
11.4 Novartis
11.4.1 Novartis Corporation Information
11.4.2 Novartis Business Overview
11.4.3 Novartis AI In Drug Development Product Features and Attributes
11.4.4 Novartis AI In Drug Development Revenue and Gross Margin (2021-2026)
11.4.5 Novartis AI In Drug Development Revenue by Product in 2025
11.4.6 Novartis AI In Drug Development Revenue by Application in 2025
11.4.7 Novartis AI In Drug Development Revenue by Geographic Area in 2025
11.4.8 Novartis AI In Drug Development SWOT Analysis
11.4.9 Novartis Recent Developments
11.5 Sanofi
11.5.1 Sanofi Corporation Information
11.5.2 Sanofi Business Overview
11.5.3 Sanofi AI In Drug Development Product Features and Attributes
11.5.4 Sanofi AI In Drug Development Revenue and Gross Margin (2021-2026)
11.5.5 Sanofi AI In Drug Development Revenue by Product in 2025
11.5.6 Sanofi AI In Drug Development Revenue by Application in 2025
11.5.7 Sanofi AI In Drug Development Revenue by Geographic Area in 2025
11.5.8 Sanofi AI In Drug Development SWOT Analysis
11.5.9 Sanofi Recent Developments
11.6 Roche
11.6.1 Roche Corporation Information
11.6.2 Roche Business Overview
11.6.3 Roche AI In Drug Development Product Features and Attributes
11.6.4 Roche AI In Drug Development Revenue and Gross Margin (2021-2026)
11.6.5 Roche Recent Developments
11.7 Insilico Medicine
11.7.1 Insilico Medicine Corporation Information
11.7.2 Insilico Medicine Business Overview
11.7.3 Insilico Medicine AI In Drug Development Product Features and Attributes
11.7.4 Insilico Medicine AI In Drug Development Revenue and Gross Margin (2021-2026)
11.7.5 Insilico Medicine Recent Developments
11.8 Exscientia
11.8.1 Exscientia Corporation Information
11.8.2 Exscientia Business Overview
11.8.3 Exscientia AI In Drug Development Product Features and Attributes
11.8.4 Exscientia AI In Drug Development Revenue and Gross Margin (2021-2026)
11.8.5 Exscientia Recent Developments
11.9 BenevolentAI
11.9.1 BenevolentAI Corporation Information
11.9.2 BenevolentAI Business Overview
11.9.3 BenevolentAI AI In Drug Development Product Features and Attributes
11.9.4 BenevolentAI AI In Drug Development Revenue and Gross Margin (2021-2026)
11.9.5 BenevolentAI Recent Developments
11.10 Recursion Pharmaceuticals
11.10.1 Recursion Pharmaceuticals Corporation Information
11.10.2 Recursion Pharmaceuticals Business Overview
11.10.3 Recursion Pharmaceuticals AI In Drug Development Product Features and Attributes
11.10.4 Recursion Pharmaceuticals AI In Drug Development Revenue and Gross Margin (2021-2026)
11.10.5 Company Ten Recent Developments
11.11 Atomwise
11.11.1 Atomwise Corporation Information
11.11.2 Atomwise Business Overview
11.11.3 Atomwise AI In Drug Development Product Features and Attributes
11.11.4 Atomwise AI In Drug Development Revenue and Gross Margin (2021-2026)
11.11.5 Atomwise Recent Developments
11.12 Isomorphic Labs
11.12.1 Isomorphic Labs Corporation Information
11.12.2 Isomorphic Labs Business Overview
11.12.3 Isomorphic Labs AI In Drug Development Product Features and Attributes
11.12.4 Isomorphic Labs AI In Drug Development Revenue and Gross Margin (2021-2026)
11.12.5 Isomorphic Labs Recent Developments
11.13 XtalPi
11.13.1 XtalPi Corporation Information
11.13.2 XtalPi Business Overview
11.13.3 XtalPi AI In Drug Development Product Features and Attributes
11.13.4 XtalPi AI In Drug Development Revenue and Gross Margin (2021-2026)
11.13.5 XtalPi Recent Developments
11.14 Deep Genomics
11.14.1 Deep Genomics Corporation Information
11.14.2 Deep Genomics Business Overview
11.14.3 Deep Genomics AI In Drug Development Product Features and Attributes
11.14.4 Deep Genomics AI In Drug Development Revenue and Gross Margin (2021-2026)
11.14.5 Deep Genomics Recent Developments
11.15 Relay Therapeutics
11.15.1 Relay Therapeutics Corporation Information
11.15.2 Relay Therapeutics Business Overview
11.15.3 Relay Therapeutics AI In Drug Development Product Features and Attributes
11.15.4 Relay Therapeutics AI In Drug Development Revenue and Gross Margin (2021-2026)
11.15.5 Relay Therapeutics Recent Developments
12 AI In Drug Development Value Chain and Ecosystem Analysis
12.1 AI In Drug Development Value Chain (Ecosystem Structure)
12.2 Upstream Analysis
12.2.1 Key Technologies, Platforms and Infrastructure
12.3 Midstream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 AI In Drug Development Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global AI In Drug Development Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
TABLE OF FIGURES
List of Tables
Table 1. Global AI In Drug Development Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Table 2. Global AI In Drug Development Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Table 3. Global AI In Drug Development Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 4. Global AI In Drug Development Revenue by Region (US$ Million), 2021-2026
Table 5. Global AI In Drug Development Revenue by Region (US$ Million), 2027-2032
Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 7. Global AI In Drug Development Revenue by Players (US$ Million), 2021-2026
Table 8. Global AI In Drug Development Revenue-Based Market Share by Players (2021-2026)
Table 9. Global Key Players’Ranking Shift (2024 vs 2025) (Based on Revenue)
Table 10. Global Companies by Tier (Tier 1, Tier 2, and Tier 3), based on AI In Drug Development Revenue, 2025
Table 11. Global AI In Drug Development Average Gross Margin (%) by Player (2021 vs 2025)
Table 12. Global AI In Drug Development Companies Headquarters
Table 13. Global AI In Drug Development Market Concentration Ratio (CR5)
Table 14. Key Market Entrant/Exit (2021-2025) – Drivers & Impact Analysis
Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 16. Global AI In Drug Development Revenue by Type (US$ Million), 2021-2026
Table 17. Global AI In Drug Development Revenue by Type (US$ Million), 2027-2032
Table 18. Key Product Attributes and Differentiation
Table 19. Global AI In Drug Development Revenue by Application (US$ Million), 2021-2026
Table 20. Global AI In Drug Development Revenue by Application (US$ Million), 2027-2032
Table 21. AI In Drug Development High-Growth Sectors Demand CAGR (2026-2032)
Table 22. Top Customers by Region
Table 23. Top Customers by Application
Table 24. North America AI In Drug Development Growth Accelerators and Market Barriers
Table 25. North America AI In Drug Development Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 26. Europe AI In Drug Development Growth Accelerators and Market Barriers
Table 27. Europe AI In Drug Development Revenue Grow Rate (CAGR) by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 28. Asia-Pacific AI In Drug Development Growth Accelerators and Market Barriers
Table 29. Asia-Pacific AI In Drug Development Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 30. Central and South America AI In Drug Development Investment Opportunities and Key Challenges
Table 31. Central and South America AI In Drug Development Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 32. Middle East and Africa AI In Drug Development Investment Opportunities and Key Challenges
Table 33. Middle East and Africa AI In Drug Development Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 34. Pfizer Corporation Information
Table 35. Pfizer Description and Major Businesses
Table 36. Pfizer Product Features and Attributes
Table 37. Pfizer Revenue (US$ Million) and Gross Margin (2021-2026)
Table 38. Pfizer Revenue Proportion by Product in 2025
Table 39. Pfizer Revenue Proportion by Application in 2025
Table 40. Pfizer Revenue Proportion by Geographic Area in 2025
Table 41. Pfizer AI In Drug Development SWOT Analysis
Table 42. Pfizer Recent Developments
Table 43. AstraZeneca Corporation Information
Table 44. AstraZeneca Description and Major Businesses
Table 45. AstraZeneca Product Features and Attributes
Table 46. AstraZeneca Revenue (US$ Million) and Gross Margin (2021-2026)
Table 47. AstraZeneca Revenue Proportion by Product in 2025
Table 48. AstraZeneca Revenue Proportion by Application in 2025
Table 49. AstraZeneca Revenue Proportion by Geographic Area in 2025
Table 50. AstraZeneca AI In Drug Development SWOT Analysis
Table 51. AstraZeneca Recent Developments
Table 52. Johnson & Johnson Corporation Information
Table 53. Johnson & Johnson Description and Major Businesses
Table 54. Johnson & Johnson Product Features and Attributes
Table 55. Johnson & Johnson Revenue (US$ Million) and Gross Margin (2021-2026)
Table 56. Johnson & Johnson Revenue Proportion by Product in 2025
Table 57. Johnson & Johnson Revenue Proportion by Application in 2025
Table 58. Johnson & Johnson Revenue Proportion by Geographic Area in 2025
Table 59. Johnson & Johnson AI In Drug Development SWOT Analysis
Table 60. Johnson & Johnson Recent Developments
Table 61. Novartis Corporation Information
Table 62. Novartis Description and Major Businesses
Table 63. Novartis Product Features and Attributes
Table 64. Novartis Revenue (US$ Million) and Gross Margin (2021-2026)
Table 65. Novartis Revenue Proportion by Product in 2025
Table 66. Novartis Revenue Proportion by Application in 2025
Table 67. Novartis Revenue Proportion by Geographic Area in 2025
Table 68. Novartis AI In Drug Development SWOT Analysis
Table 69. Novartis Recent Developments
Table 70. Sanofi Corporation Information
Table 71. Sanofi Description and Major Businesses
Table 72. Sanofi Product Features and Attributes
Table 73. Sanofi Revenue (US$ Million) and Gross Margin (2021-2026)
Table 74. Sanofi Revenue Proportion by Product in 2025
Table 75. Sanofi Revenue Proportion by Application in 2025
Table 76. Sanofi Revenue Proportion by Geographic Area in 2025
Table 77. Sanofi AI In Drug Development SWOT Analysis
Table 78. Sanofi Recent Developments
Table 79. Roche Corporation Information
Table 80. Roche Description and Major Businesses
Table 81. Roche Product Features and Attributes
Table 82. Roche Revenue (US$ Million) and Gross Margin (2021-2026)
Table 83. Roche Recent Developments
Table 84. Insilico Medicine Corporation Information
Table 85. Insilico Medicine Description and Major Businesses
Table 86. Insilico Medicine Product Features and Attributes
Table 87. Insilico Medicine Revenue (US$ Million) and Gross Margin (2021-2026)
Table 88. Insilico Medicine Recent Developments
Table 89. Exscientia Corporation Information
Table 90. Exscientia Description and Major Businesses
Table 91. Exscientia Product Features and Attributes
Table 92. Exscientia Revenue (US$ Million) and Gross Margin (2021-2026)
Table 93. Exscientia Recent Developments
Table 94. BenevolentAI Corporation Information
Table 95. BenevolentAI Description and Major Businesses
Table 96. BenevolentAI Product Features and Attributes
Table 97. BenevolentAI Revenue (US$ Million) and Gross Margin (2021-2026)
Table 98. BenevolentAI Recent Developments
Table 99. Recursion Pharmaceuticals Corporation Information
Table 100. Recursion Pharmaceuticals Description and Major Businesses
Table 101. Recursion Pharmaceuticals Product Features and Attributes
Table 102. Recursion Pharmaceuticals Revenue (US$ Million) and Gross Margin (2021-2026)
Table 103. Recursion Pharmaceuticals Recent Developments
Table 104. Atomwise Corporation Information
Table 105. Atomwise Description and Major Businesses
Table 106. Atomwise Product Features and Attributes
Table 107. Atomwise Revenue (US$ Million) and Gross Margin (2021-2026)
Table 108. Atomwise Recent Developments
Table 109. Isomorphic Labs Corporation Information
Table 110. Isomorphic Labs Description and Major Businesses
Table 111. Isomorphic Labs Product Features and Attributes
Table 112. Isomorphic Labs Revenue (US$ Million) and Gross Margin (2021-2026)
Table 113. Isomorphic Labs Recent Developments
Table 114. XtalPi Corporation Information
Table 115. XtalPi Description and Major Businesses
Table 116. XtalPi Product Features and Attributes
Table 117. XtalPi Revenue (US$ Million) and Gross Margin (2021-2026)
Table 118. XtalPi Recent Developments
Table 119. Deep Genomics Corporation Information
Table 120. Deep Genomics Description and Major Businesses
Table 121. Deep Genomics Product Features and Attributes
Table 122. Deep Genomics Revenue (US$ Million) and Gross Margin (2021-2026)
Table 123. Deep Genomics Recent Developments
Table 124. Relay Therapeutics Corporation Information
Table 125. Relay Therapeutics Description and Major Businesses
Table 126. Relay Therapeutics Product Features and Attributes
Table 127. Relay Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026)
Table 128. Relay Therapeutics Recent Developments
Table 129. Technologies, Platforms and Infrastructure
Table 130. Distributors List
Table 131. Market Trends and Market Evolution
Table 132. Market Drivers and Opportunities
Table 133. Market Challenges, Risks, and Restraints
Table 134. Research Programs/Design for This Report
Table 135. Key Data Information from Secondary Sources
Table 136. Key Data Information from Primary Sources
List of Figures
Figure 1. Global AI In Drug Development Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Figure 2. Software Product Picture
Figure 3. Services Product Picture
Figure 4. Global AI In Drug Development Market Size Growth Rate , 2021 vs 2025 vs 2032 (US$ Million)
Figure 5. Global AI In Drug Development Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Figure 6. Biopharmaceuticals
Figure 7. Synthetic Pharmaceuticals
Figure 8. Others
Figure 9. AI In Drug Development Report Years Considered
Figure 10. Global AI In Drug Development Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 11. Global AI In Drug Development Revenue (US$ Million), 2021-2032
Figure 12. Global AI In Drug Development Revenue (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Figure 13. Global AI In Drug Development Revenue-Based Market Share by Region (2021-2032)
Figure 14. Global AI In Drug Development Revenue-Based Market Share Ranking (2025)
Figure 15. Tier Distribution by Revenue Contribution (2021 vs 2025)
Figure 16. Software Revenue-Based Market Share by Player in 2025
Figure 17. Services Revenue-Based Market Share by Player in 2025
Figure 18. Global AI In Drug Development Revenue-Based Market Share by Type (2021-2032)
Figure 19. Global AI In Drug Development Revenue-Based Market Share by Application (2021-2032)
Figure 20. North America AI In Drug Development Revenue YoY (US$ Million), 2021-2032
Figure 21. North America Top 5 Players AI In Drug Development Revenue (US$ Million) in 2025
Figure 22. North America AI In Drug Development Revenue (US$ Million) by Application (2021-2032)
Figure 23. US AI In Drug Development Revenue (US$ Million), 2021-2032
Figure 24. Canada AI In Drug Development Revenue (US$ Million), 2021-2032
Figure 25. Mexico AI In Drug Development Revenue (US$ Million), 2021-2032
Figure 26. Europe AI In Drug Development Revenue YoY (US$ Million), 2021-2032
Figure 27. Europe Top 5 Players AI In Drug Development Revenue (US$ Million) in 2025
Figure 28. Europe AI In Drug Development Revenue (US$ Million) by Application (2021-2032)
Figure 29. Germany AI In Drug Development Revenue (US$ Million), 2021-2032
Figure 30. France AI In Drug Development Revenue (US$ Million), 2021-2032
Figure 31. U.K. AI In Drug Development Revenue (US$ Million), 2021-2032
Figure 32. Italy AI In Drug Development Revenue (US$ Million), 2021-2032
Figure 33. Russia AI In Drug Development Revenue (US$ Million), 2021-2032
Figure 34. Asia-Pacific AI In Drug Development Revenue YoY (US$ Million), 2021-2032
Figure 35. Asia-Pacific Top 8 Players AI In Drug Development Revenue (US$ Million) in 2025
Figure 36. Asia-Pacific AI In Drug Development Revenue (US$ Million) by Application (2021-2032)
Figure 37. Indonesia AI In Drug Development Revenue (US$ Million), 2021-2032
Figure 38. Japan AI In Drug Development Revenue (US$ Million), 2021-2032
Figure 39. South Korea AI In Drug Development Revenue (US$ Million), 2021-2032
Figure 40. Australia AI In Drug Development Revenue (US$ Million), 2021-2032
Figure 41. India AI In Drug Development Revenue (US$ Million), 2021-2032
Figure 42. Indonesia AI In Drug Development Revenue (US$ Million), 2021-2032
Figure 43. Vietnam AI In Drug Development Revenue (US$ Million), 2021-2032
Figure 44. Malaysia AI In Drug Development Revenue (US$ Million), 2021-2032
Figure 45. Philippines AI In Drug Development Revenue (US$ Million), 2021-2032
Figure 46. Singapore AI In Drug Development Revenue (US$ Million), 2021-2032
Figure 47. Central and South America AI In Drug Development Revenue YoY (US$ Million), 2021-2032
Figure 48. Central and South America Top 5 Players AI In Drug Development Revenue (US$ Million) in 2025
Figure 49. Central and South America AI In Drug Development Revenue (US$ Million) by Application (2021-2032)
Figure 50. Brazil AI In Drug Development Revenue (US$ Million), 2021-2032
Figure 51. Argentina AI In Drug Development Revenue (US$ Million), 2021-2032
Figure 52. Middle East and Africa AI In Drug Development Revenue YoY (US$ Million), 2021-2032
Figure 53. Middle East and Africa Top 5 Players AI In Drug Development Revenue (US$ Million) in 2025
Figure 54. Middle East and Africa AI In Drug Development Revenue (US$ Million) by Application (2021-2032)
Figure 55. GCC Countries AI In Drug Development Revenue (US$ Million), 2021-2032
Figure 56. Israel AI In Drug Development Revenue (US$ Million), 2021-2032
Figure 57. Egypt AI In Drug Development Revenue (US$ Million), 2021-2032
Figure 58. South Africa AI In Drug Development Revenue (US$ Million), 2021-2032
Figure 59. AI In Drug Development Value Chain Mapping
Figure 60. Channels of Distribution (Direct Vs Distribution)
Figure 61. Bottom-up and Top-down Approaches for This Report
Figure 62. Data Triangulation
Figure 63. Key Executives Interviewed
KEY QUESTIONS ADDRESSED BY THE REPORT
What is the annual compound growth rate of the global AI In Drug Development market size from 2026 to 2032?
The annual compound growth rate of the global AI In Drug Development market is 56.0% 2026 to 2032.
What was the global market size of AI In Drug Development in 2032?
Which region is expected to have the highest market share?
Which companies rank high in the global AI In Drug Development market?
What was the global market size of AI In Drug Development in 2026?
Related Reports
Global AI In Drug Development Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global AI In Drug Development market size was US$ 581 million in 2025 and is forecast to reach a readjusted size of US$ 12590 million by 2032 with a CAGR of 56.0% during the forecast period 2026-2032.
Published Date: 2026-03-12
Pages: 98
USD 4250.00
(Single User License)
Global AI In Drug Development Market Research Report 2026
The global AI In Drug Development market was valued at US$ 581 million in 2025 and is anticipated to reach US$ 12590 million by 2032, at a CAGR of 56.0% from 2026 to 2032.
Published Date: 2026-03-12
Pages: 112
USD 2900.00
(Single User License)
AI In Drug Development - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for AI In Drug Development was estimated to be worth US$ 581 million in 2025 and is projected to reach US$ 12590 million, growing at a CAGR of 56.0% from 2026 to 2032.
Published Date: 2026-03-09
Pages: 108
USD 3950.00
(Single User License)
Global AI In Drug Development Market Research Report 2025
The global market for AI In Drug Development was valued at US$ 209 million in the year 2024 and is projected to reach a revised size of US$ 8369 million by 2031, growing at a CAGR of 56.0% during the forecast period.
Published Date: 2025-07-24
Pages: 87
USD 2900.00
(Single User License)
AI In Drug Development - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for AI In Drug Development was estimated to be worth US$ 209 million in 2024 and is forecast to a readjusted size of US$ 8369 million by 2031 with a CAGR of 56.0% during the forecast period 2025-2031.
Published Date: 2025-07-24
Pages: 102
USD 3950.00
(Single User License)
Global AI In Drug Development Market Outlook, In‑Depth Analysis & Forecast to 2031
The global AI In Drug Development market is projected to grow from US$ 209 million in 2024 to US$ 8369 million by 2031, at a CAGR of 56.0% (2025-2031), driven by critical product segments and diverse end‑use applications.
Published Date: 2025-07-24
Pages: 138
USD 4900.00
(Single User License)
Global AI In Drug Development Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global AI In Drug Development market size was US$ 209 million in 2024 and is forecast to a readjusted size of US$ 8369 million by 2031 with a CAGR of 56.0% during the forecast period 2025-2031.
Published Date: 2025-07-24
Pages: 95
USD 4250.00
(Single User License)
Global AI In Drug Development Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global AI In Drug Development market size was US$ 581 million in 2025 and is forecast to reach a readjusted size of US$ 12590 million by 2032 with a CAGR of 56.0% during the forecast period 2026-2032.
Published: 2026-03-12
Pages: 98
USD 4250.00 (Single User License)Global AI In Drug Development Market Research Report 2026
The global AI In Drug Development market was valued at US$ 581 million in 2025 and is anticipated to reach US$ 12590 million by 2032, at a CAGR of 56.0% from 2026 to 2032.
Published: 2026-03-12
Pages: 112
USD 2900.00 (Single User License)AI In Drug Development - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for AI In Drug Development was estimated to be worth US$ 581 million in 2025 and is projected to reach US$ 12590 million, growing at a CAGR of 56.0% from 2026 to 2032.
Published: 2026-03-09
Pages: 108
USD 3950.00 (Single User License)Global AI In Drug Development Market Research Report 2025
The global market for AI In Drug Development was valued at US$ 209 million in the year 2024 and is projected to reach a revised size of US$ 8369 million by 2031, growing at a CAGR of 56.0% during the forecast period.
Published: 2025-07-24
Pages: 87
USD 2900.00 (Single User License)AI In Drug Development - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for AI In Drug Development was estimated to be worth US$ 209 million in 2024 and is forecast to a readjusted size of US$ 8369 million by 2031 with a CAGR of 56.0% during the forecast period 2025-2031.
Published: 2025-07-24
Pages: 102
USD 3950.00 (Single User License)Global AI In Drug Development Market Outlook, In‑Depth Analysis & Forecast to 2031
The global AI In Drug Development market is projected to grow from US$ 209 million in 2024 to US$ 8369 million by 2031, at a CAGR of 56.0% (2025-2031), driven by critical product segments and diverse end‑use applications.
Published: 2025-07-24
Pages: 138
USD 4900.00 (Single User License)Global AI In Drug Development Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global AI In Drug Development market size was US$ 209 million in 2024 and is forecast to a readjusted size of US$ 8369 million by 2031 with a CAGR of 56.0% during the forecast period 2025-2031.
Published: 2025-07-24
Pages: 95
USD 4250.00 (Single User License)
CHOOSE LICENSE TYPE
USD 4900.00
USD 7350.00
USD 9800.00
Add to Cart
Buy Now
HAVE A QUESTION?
General Email:
REPORT COVERAGE
DESCRIPTION
OVERVIEW
MARKET SEGMENTATION
CHAPTER OUTLINE
WHY THIS REPORT
QYRESEARCH'S STRENGTHS
TABLE OF CONTENTS
TABLE OF FIGURES
RLEATED REPORTS
INTEREST IN THIS REPORT?
Get A Free Sample
Request For Quotation
OR
NEED A CUSTOMIZED REPORT?
Customized Report
Request Sample
Pre-Order Enquiry
Add to Cart
Buy Now